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ABSTRACT 
Forty eight patients with previously untreated diffuse histiocytic*lymphoma 
(DHL) were treated prospectively with ACOMLA (hydroxydaunorubicin, 
cyclophosphamide, vincristine, methotrexate with leucovorin, and cytosine 
arabinoside) or CHOP-B (cylophosphamide, hydroxydaunorubicin, vincristine, 
prednisone, and bleomycin). Forty six of these patients were classified 
by the Lukes-Collins classification with the identification of 13 large cleaved 
follicular center cell, 7 large non-cleaved follicular center cell, 14 B-cell 
immunoblastic, 8 T-cell immunoblastic, and 4 large cell unclassified lymphomas. 
There was no difference in survival advantage between the two treatments. 
Overall complete response rate was 70% (with ACOMLA having a response rate of 
68% and CHOP-B 71%). Of these, 4 of the ACOMLA patients and 3 of the CHOP-B 
patients have relapsed. Median follow-up time is 32 months. Median survival 
for all patients has not yet been reached. Drug toxicity was substantial with 
3 drug related deaths. ACOMLA caused slightly more sepsis but the difference 
was not significant. Patients with follicular center cell (FCC) lymphomas had 
a significant survival advantage over patients with immunoblastic sarcomas 
(p=0.01). No difference in survival was found between the cleaved and 
non-cleaved FCC types. Age, sex, stage, site of involvement, or presence of 
symptoms were not significantly correlated with survival. Immunoblastic 
sarcomas (B and T cell types) appear to be more resistant to current 
chemotherapeutic regimens and may warrant more aggressive treatment. 
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The Non-Hodgkin's lymphomas (NHL) are a diverse group of neoplasms*of the 
lymph nodes and lymphoid components of other tissues. The classification of 
these disorders has paralleled the scientific understanding of them and has 
been a source of controversy for many years. Ideally, the classification of 
any disease should be 1) easy to use, 2) reproducible, 3) scientifically 
accurate, and 4) prognostically and therapeutically significant. The 
production of such a scheme has been the theme of research done on these 
neoplasms since they were first described one hundred and fifty years ago. 
This paper will present a brief history of the development of the 
classifications of non-Hodgkin's lymphomas as an introduction to a report of a 
study done at Yale between May, 1976 and April, 1982. This study is a 
prospective randomized trial of two different chemotherapeutic regimens for one 
of the most aggressive of the non-Hodgkin's lymphomas - diffuse histiocytic 
lymphoma. This trial was performed in such a way as to allow implications to 
be made on the ability of the Lukes-Collins classification (of the NHL) to 
identify subsets of diffuse histiocytic lymphoma that are refractory to 
treatment so that a more efficacious treatment can be designed for them. 

2 
GENERAL HISTORICAL BACKGROUND 
Interest in the nature of lymphomas is generally considered to have begun 
in 1832, (though some will cite the work of Malpighi in 1661 or that of 
Morgagni in 1779), with a published report by the now-famous Thomas Hodgkin 
entitled "On some morbid appearances of the absorbent glands and the spleen" 
(1). In this report, Hodgkin presented the clinical features and pathologic 
appearance of seven patients with generalized lymphadenopathy and splenomegaly 
stating that "as far as could be ascertained from observation, or from what 
could be collected from the history of cases, this enlargement of the glands 
appeared to be a primitive affection of those bodies, rather than the result of 
an irritation propagated to them from some ulcerated surface or other inflamed 
texture through the medium of their inferent vessels." Hodgkin also noted the 
condition of the spleen which was, in a few of the cases, "thickly pervaded 
with defined bodies of various sizes in structure resembling that of the 
diseased glands" and concluded that there was a "close connection between the 
derangement of the glands and that of the spleen". He believed that the 
involvement of the spleen was a secondary event to involvement of the lymph 
nodes "and on this account may not always have been produced, when that 
[derangement] of the glands or some other disease carried off the patient" 
(1). 
This work by Hodgkin seems to have been largely ignored until the work of 
Sir Samuel Wilks. Wilks published a report of 15 patients with a similar 
disorder "thirteen of which resembled in all particulars...[those] which Mr 




that this disease represented a distinct and separate pathological condition 
among all of the other afflictions of the lymph nodes and spleen. He also 
noticed the "remarkable anemia" and it is clear that he separated this disease 
from leukemia. Finally, in an act of chivalry, he preserved his predecessors 
name in history by naming the disorder "Hodgkin's" disease (3). 
Before the work of Wilks, the German pathologist Virchow too had 
distinguished this disorder from leukemia, known at that time to be a disease 
of the peripheral blood and bone marrow, calling it "lymphosarcoma" (4). It 
remained until 1893 for Kundrat to develop histologic criteria for the 
diagnosis of lymphosarcoma, in order to distinguish it from "aleukemic 
leukemia" another term coined by Virchow, as well as from "lymphogranula", 
"lymphogranulomatosis" and a number of other synonyms for Hodgkin's disease 
(5). It remained, however, until 1902 for Dorothy Reed to describe the 
multinucleate giant cells (while she was still a medical student) which now 
bear her name, and develop histopathologic criteria for the diagnosis of 
Hodgkin's disease, which was felt to be a separate clinico-pathologic entity 
(3,6). 
In 1926, Fox went back to the original material preserved by Hodgkin and, 
using the criteria developed by Reed and Sternberg, confirmed the diagnosis of 
Hodgkin's disease in only three of the original seven cases thus confirming the 
presence of a separate "non"-Hodgkin's lymphoma (7). Ewing, in 1928, described 
two kinds of "lymphosarcoma”: "malignant lymphosarcoma" composed of smaller 
cells, and "reticulum cell sarcoma" composed of larger ones. He believed that 
these tumors arose from either reticulum cells or from lymphocytes in the 
germinal centers of lymph nodes (8). Two years later Roulet published 
' 
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criteria for the diagnosis of "reticulum cell sarcoma" (9), and it was at this 
time that Brill described a group of lymphomas with "follicular" architecture 
which were radiosensitive and thus had a relatively benign prognosis*(10). 
This lymphoma came to be called "giant follicular lymphoma" or 
"Brill-Symmer's" disease after the work of N.E. Brill (11). 
Thus, during the early part of this century pathologists generally divided 
the non-Hodgkin's lymphomas (NHL) into three groups based upon microscopic 
architecture; giant follicular lymphoma (or synonyms), lymphosarcoma, and 
reticulum cell sarcoma. While this loose classification represented the best 
understanding of the disease at that time (as well as the best in histologic 
technology), it proved to be of limited usefulness as it was difficult to 
reproduce, and, other than the relatively benign prognosis of the giant 





In spite of its limited usefulness, this classification scheme persisted 
until the early sixties when a classification developed by Rappaport, Winters, 
and Hicks, came into general use. These pathologists believed that a 
classification scheme should be based primarily on cytologic grounds (i.e. cell 
types) with a secondary emphasis on architecture (14). Their system, first 
published in 1956, further modified in 1966 and 1978 (15,16), proposed five 
groups of NHL (see table 1) divided by cell type (lymphocytic, histiocytic, or 
mixed lymphocytic-histiocytic) with each cell type showing two types of 
architecture; "nodular" where the lymphomatous cells are clustered around in 
discrete identifiable nodules or "diffuse” where the lymphomatous cells have 
spread to the point that they totally efface the underlying nodal structure. 
The lymphocytic groups are further modified by whether the cells are well or 
poorly differentiated. Table 2 shows the Rappaport classification in relation 
to the system that preceded it. The latest version of the Rappaport 
classification is shown in Table 3, and Figure 1 illustrates the essential 
morphologic characterizations. 
Since its original publication in 1956, numerous studies have confirmed 
Rappaport's original assertion that, within each cell grouping, a lymphoma with 
a nodular (follicular) architecture confers a better prognosis than one with a 
diffuse pattern and that a lymphoma composed of lymphocytes, regardless of 
degree of differentiation, confers a better prognosis than a lymphoma composed 
of either mixed cells or histiocytes (14,16-21). Having thus been proven to 
provide valuable prognostic information, the Rappaport classification 
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gained wide acceptance and became the classification that was used in clinical 
trials world-wide. 
However, during the late sixties and early seventies new information was 
being discovered about the structure, function, and maturation of lymphocytes 
that began to cast doubt upon the scientific accuracy of the Rappaport 
classification, which was based upon morphologic criteria alone, and did not 
include the new immunologic terminology. It was shown, for example, that the 
histiocytes of the Rappaport classification were not indeed "true" histiocytes 
but rather transformed B-lymphocytes which resembled histiocytes (22). In 
addition, studies were published that indicated that nodular lymphomas appeared 
to be uniformly composed of cells of B-lymphocyte origin (23). From these 
discoveries and others it became apparent to researchers at many centers that a 
classification scheme needed to be developed which would include modern 
concepts of the immune system. The search for the "conceptually relevant" 
classification scheme resulted in a veritable explosion of "new-improved" 
classifications which confounded clinician and researcher alike and left the 
mere student hopelessly lost. As the dust settled, however, it became clear 
that there remained no less than six classification schemes (excluding minor 
modifications) with the proponents of each claiming superiority over the 
others. These systems are (in alphabetical order): The British National 
Lymphoma Investigation (BNLI) classification, the Dorfman classification, the 
Lukes-Collins classification, the Kiel classification, the Rappaport 
classification, and the World Health Organization classification (24-27). 
While the details of the BNLI, Dorfman, Kiel, and WHO classifications are 
beyond the scope of this paper, the general outline and salient features of 
each will be given after a description of the Lukes-Collins classification. 
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RAPPAPORT CLASSIFICATION (Original) 






(Adapted from Rappaport (14)) 
RAPPAPORT CLASSIFICATION AND ••OLD" TERMINOLOGY 
Rappaport Old Terminology 
Nodular lymphomas - Giant Follicular Lymphoma 
(all cell types) 
Diffuse Lymphomas 
Lymphocytic - Lymphosarcoma 
Mixed - Reticulum Cell Sarcoma 
Histiocytic - Reticulum Cell Sarcoma 
Undifferentiated - Reticulum Cell Sarcoma 
(Adapted from Rappaport (14)) 
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Table 3. RAPPAPORT CLASSIFICATION (UPDATED) WITH FREQUENCY OF OCCURENCE 




















(+ plasmacytoid features) 
Lymphocytic, Poorly-differentiated 
(+ plasmacytoid features) 
Lymphoblastic, (+ convolutions) 
Mixed, Histiocytic and Lymphocytic 
Histiocytic (+ sclerosis) 
Undifferentiated (Burkitt's and 
non-Burkitt's) 
UNCLASSIFIED 
(Adapted from NCI sponsored study of NHL (23)) 
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The Lukes-Collins Classification 
The classification scheme for the NHL proposed by Lukes and Collins in 
1974, subsequently modified in 1975 and 1976 (28-32), was one of the first to 
attempt to incorporate concepts of modern immunology. It is currently one of 
those most widely used in the U.S. but it is not without its critics. Lukes 
and Collins based their system on the premise that, since the malignant 
lymphoma are neoplasms of the immune system, they should be classified 
according to their B or T cell origins. They based their work on studies done 
in their own and in other’s laboratories, which traced the normal development 
and transformation of lymphocytes under antigenic or mitogenic stimulation. 
Comparing this normal development with cytologic patterns in lymphomatous 
tissue, Lukes and Collins proposed that malignant lymphomas develop from a 
"block" or "swtich-on" (or derepression) in the normal transformation of 
lymphocytes (30). 
Tracing the normal transformation of a lymphocyte, either under antigenic 
or mitogenic stimulation, the cell can be seen to undergo four distinct phases 
of development which take place within the germinal follicle (also called the 
follicular center). First, the stimulated B-cell grows slightly and its 
nucleus develops a sharp infolding of the nuclear membrane which causes the 
nucleus to take on a bilobate or multilobate appearance. This infolding is 
called "cleavage" and is readily apparent under light microscopy with normal 
stains. At this stage, the cell is called a small cleaved follicular center 
cell (sclFCC). (It should be noted here that the word "follicular" is used in 
a different context than previously. Here "follicular" refers to a location 
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within a lymph node whereas previously, in the discussion of the Rappaport 
classification, "follicular" referred to a particular type of nodal 
architecture. It will be seen that "follicular" center cell lymphomas can take 
on a "follicular" architecture. As this has been known to confuse students of 
the lymphomas, the word "nodular" will be used instead of "follicular" when 
referring to architecture.) The cell then continues to grow, retaining its 
cleavage, to become, appropriately enough, a large cleaved follicular center 
cell (lclFCC). 
At this point, the cell begins to show signs of mitotic activity, with mild 
affinity for pyronin stain (pyroninophilia) indicating an increase in protein 
synthesis, and the nuclear cleavage disappears. The cell is now called a 
small non-cleaved follicular center cell (sncFCC). Growth continues as the 
cell develops prominent nucleoli and the cell is now called a large non-cleaved 
follicular center cell (IncFCC), and can grow to as large as four times the 
size of a non-stimulated lymphcyte. 
In this normal development it is apparent that the non-cleaved cells are 
the cells engaged in active replication while the cleaved cells represent their 
quiescent counterparts. Transformation of the stimulated lymphocyte continues 
but now takes place outside the follicle in the interfollicular area where the 
cell becomes an even more avid replicator as it undergoes transformation into 
an immunoblast. The cell becomes markedly pyroninophilic, develops a larger 
nucleus and many prominent nucleoli become visible. The immunoblasts 
proliferate into daughter cells which become either the antibody-producing 
plasma cells or small "memory" lymphocytes. These events in the normal B-cell 
transformation are depicted in Figure 2. 
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Figure 2. B and T Ceil Trane format ion 
lendritic 
ticulum cell 










T - lymphocyte 
plasma cell 
immunoblast (T-Cell) 
(adapted from J. Waldron handout 10/80) 
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Small T-cell lymphocytes also have the potential of undergoing blast 
transformation but do so outside the germinal follicles in the parafollicular 
area and do not develop nuclear cleavage. Instead, as they pass from* 
lymphocyte to immunoblast, they develop multiple nuclear lobulations which is 
called "chicken-footprinting" (33). 
Believing then that lymphomatous development represents a block or 
derepression in the normal pattern of lymphocyte transformation, Lukes and 
Collins proposed nine different categories of lymphomas each corresponding to a 
block at a particular point of development. This is shown schematically with 
the lymphoma categories superimposed upon normal development in Figure 3. The 
formal Lukes-Collins classification is listed in Table 4 and will be described 
briefly. 
B-Cell Lymphomas 
Small B-cell Lymphoma; This lymphoma is composed of small, well- 
differentiated lymphocytes which appear like the unstimulated lymphocytes shown 
in Figure 2. The appearance of nodes from patients with small B-cell lymphomas 
is indistinguishable from those of patients with chronic lymphocytic leukemia 
(CLL) and indeed this disease often develops a leukemic component. 
Plasmacytoid Lymphocytic Lymphoma: This lymphoma has a similar appearance 
to the small B-cell lymphoma but is believed to arise from a block at a 
different point and the cells contain plasmacyte features. 
Follicular Center Cell Lymphomas: Composed of transformed B-cells with a 
follicular center origin, these lymphomas contain all variants of the 
follicular center cell (FCC); cleaved and non-cleaved, small and large. They 
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can be found with or without sclerosis. It is important to stress that Lukes 
and Collins place no significance on the nodular or diffuse nature of a FCC 
lymphoma. It is felt that the nodular forms of the FCC lymphomas mer'ely 
represent the disease caught at an earlier stage before it has grown enough to 
efface the normal nodal architecture and become "diffuse" in appearance. FCC 
lymphomas are found which contain mixed cleaved and non-cleaved cells but Lukes 
and Collins do not have a category for a "mixed" cleaved-non-cleaved lymphoma. 
Instead, a FCC lymphoma is defined as non-cleaved if the node is "focally 
dominated by non-cleaved cells or the number exceeds 25% throughout" (31). 
Immunoblastic Sarcoma (B-Cell Type): These lymphomas are composed of large- 
non-cleaved cells, which are larger and have a more pyroninophilic cytoplasm 
than the large non-cleaved cells of the follicular center. They represent 
lymphomas of the fully transformed lymphocyte or immunoblast. 
T-Cell Lymphomas 
Small T-Cell Lymphoma: The small T-cell lymphoma is the T-cell counterpart 
of the small B-cell lymphoma. It, too, is associated with CLL. Morpho¬ 
logically it is similar to the B-cell lymphoma but has features by which it may 
be distinguished (34). 
Sezary Syndrome - Mycosis Fungoides: Included here for completeness, these 
disorders have been proven to be of T-cell origin. They are, however, 
lymphomatous disorders confined to the skin and have a very different natural 




Convoluted Lymphocyte: These lymphomas are composed of partially 
transformed T-lymphocytes which display the lobulation referred to as "chicken 
footprinting”. They are easily confused with small cleaved FCC but c^n be 
differentiated by the presence of these lobulations. Convoluted lymphocyte 
lymphomas are commonly associated with a thymic mass and leukemic 
transformation. 
Immunoblastic Sarcoma (T-Cell Type): The T-cell counterpart of the B-cell 
immunoblastic sarcoma, this lymphoma is a pleomorphic diffuse lymphoma with 
commonly a mixture of small and transformed lymphocytes. Nuclear irregularity 
is common as is a pale cytoplasm. The mean tumor cell size varies 
significantly from one case to another. Some of the T-immunoblastic sarcomas 
would be classified as Rappaport "histiocytic" lymphomas while others would be 
included in the mixed cell category (33,34). 
Histiocytic Lymphomas: Unlike the Rappaport classification which 
identifies a larger number of "histiocytic" lymphomas, in the Lukes-Collins 
classification a lymphoma of "true" histiocytes is rare, occurring in one of 
Lukes and Collins' early studies only in one case of three hundred reviewed. 
Identified by their large size in the Rappaport classification, most 
"histiocytic” lymphomas turn out to be composed of large FCC or of immunoblasts 
(see Table 5). The prognostic significance of this will be discussed later. 
Unidentified (U-Cell) 
Lukes and Collins deemed a lymphoma to be a U-cell lymphoma when it lacked 
any surface markers by which it could be identified. The U-cell group, 
according to them, is "...hypothetical and provides a group for those 
• 
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proliferations of lymphocytes that prove to have no discriminating cell markers 
detectable" (35). It essentially provides a "wastebasket” category and has 
been the object of some criticsm. 
Unclassifiable 
The "unclassifiable” group "...allows categorization of those processes 
that are technically unsatisfactory for precise cytologic classification but 
are sufficient for identification of the process as lymphomatous" (32). In the 
recent study by the NCI, 37% of routinely prepared slides were found to be 
"unclassifiable" by the Lukes-Collins system whereas the "unclassifiable" 
category for the other classification systems ranged from 15-30% (24). 
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Follicular Center Cell, small cleaved* 
Follicular Center Cell, large cleaved* 
Follicular Center Cell, small non-cleaved* 
Follicular Center Cell, large non-cleaved* 




*may be nodular, nodular and diffuse or diffuse, 
with or without sclerosis 
(adapted from NCI sponsored study of NHL (24)) 
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Figure 3. Lukes-Collins Classification* 
Relation to normal transformation 















T-Cell Lymphoma T-Immunoblastic 
,arcoma 
(adapted from. J. Waldron handout 10/80) 
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Prognostic Significance of Lukes-Collins Classification 
Since one of the aims of a classification system is to provide som& 
information about prognosis, the value of a system must be questioned, no 
matter how "scientifically accurate" or "conceptually relevant" it is, if it 
does not provide this information. This has been one of the more controversial 
points concerning the Lukes-Collins classification. Based as it is on presumed 
"blocks" or "switch-ons" in the path of normal lymphocyte transformation, it is 
tempting to assume that as one progresses from lymphomas composed of small 
non-transformed B-cells, which are mitotically inactive in their normal state, 
to lymphomas composed of immunoblasts, which in their normal state are poised 
ready to produce daughter cells, there would be a trend toward more aggressive 
neoplasms (32). Generally, this has been proven to be the case. Small B-cell 
lymphomas have a better prognosis than FCC lymphomas which, as a group 
(including large and small cells), have a better prognosis than immunoblastic 
sarcomas. (35). 
There has been, however, some disagreement over the prognosis of the large 
cell groups: large FCC cleaved and non-cleaved, and the immunoblastic sarcomas 
(both B and T cell origin). Most studies indicate that the prognosis for the 
immunoblastic sarcomas is worse than that of the large cell FCC lymphomas (27, 
31,35-38) although this is not a universal finding. Garvin et.al. (26) in a 22 
year retrospective review, found that there was no significant difference 
between the FCC and the immunoblastic sarcomas, although there appeared to be a 
trend toward a better prognosis for the FCC lymphomas. This study, however, 
was a retrospective review where the patients received heterogeneous therapy 
and experienced generally poor survival. There seems to be more disagreement 
. 
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over the prognosis of the other two large cell groups, the FCC large cleaved 
and the FCC large non-cleaved. One study by Strauchen et.al. (36) analyzed a 
series of 66 patients prospectively treated with either C-MOPP or BACOP (see 
section on treatment for an explanation of these acronyms). Their conclusion 
was that the large cleaved FCC had a better prognosis than the large 
non-cleaved FCC group (p<0.01). This conclusion is supported by a prospective 
study by Stein (38) and a retrospective review by Barcos et.al. (45). Nathwani 
et. al. reported in 1978 (28) a retrospective review of 202 cases of DHL in 
which the large cleaved FCC lymphomas had a better prognosis. However, more 
recently they reported another series of 162 cases in which they found no 
difference in survival between any of the Lukes-Collins subtypes of the DHL 
(64). Armitage reported a series of patients (n=31) uniformly treated with 
CHOP in which the patients with large non-cleaved lymphomas did better than 
patients with large cleaved ones (37). Garvin's (26) retrospective study noted 
no difference between the two groups. 
Comparison of Rappaport and Lukes-Collins Classifications 
Table 5 shows the rough correlations between the Rappaport and Lukes- 
Collins classifications. The most obvious difference between the two is the 
fact that the former groups the lymphomas around cell type and architecture 
while the latter groups them around their immunologic origin. While 
architecture (nodular vs. diffuse) has been shown to be of prognostic 
significance in numerous studies, Lukes and Collins have not emphasized 
architecture because it is not relevant in light of modern discoveries in 
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Immunology. As it was stated before, Lukes and Collins believe that nodular 
and diffuse lymphomas do not represent different clinical entities but rather 
reflect, within a given cell type, different stages of the same disease, with 
nodular lymphomas representing the early stages of the disease before the 
lymphomatous cells have spread and effaced the nodal architecture. 
The second major difference between the two classifications is in the area 
of the "histiocytic" lymphoma. The Rappaport classification essentially 
defines the histiocyte by its large size. The Lukes-Collins classification, on 
the other hand, stresses the relative rarity of "true" histiocytic lymphomas 
and divides the Rappaport histiocytic lymphomas into five subgroups (see Table 
5): lclFCC, LncFCC, Immunoblastic sarcoma (both B and T cell derived), and 
"true" histiocytic lymphoma. 
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Table 5. COMPARISON OF LUKES-COLLINS AND RAPPAPORT CLASSIFICATIONS 
RAPPAPORT LUKES-COLLINS 
Nodular and/or Diffuse 
* Well Differentiated 
** Poorly Differentiated 
*** Lymphocytic/Histiocytic 
(Adapted from Lukes and Collins (30)) 
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Criticism of the Lukes-Collins Classification 
While Lukes and Collins have been widely praised for having introduced 
modern understanding of lymphoid physiology into a classification scheme for 
the lymphomas, their classification is not without its critics. In a 
well-cited study of the NHL comparing the Lukes-Collins classification with the 
Rappaport classification, the authors (Rappaport being among them) criticized 
the LCC along a number of lines. They reviewed a series of 202 cases of NHL 
and classified them according to both systems and correlated this with survival 
data (28). 
First these authors found it difficult to categorize malignant lymphomas 
into separate B and T cell groups on a morphologic basis alone. "While the 
T-cell or B-cell can often be assumed or inferred from certain cytologic 
features and patterns of growth, there is no conclusive evidence that the 
number of cases in which this can be done is sufficiently large to make this 
classification suitable for use in clinical programs" (28). This criticism is 
further supported by the recent NCI study in which 37% of routinely stained 
lymphomas were found to be unclassifiable by the Lukes-Collins classification 
(compared to 15-30% for the other classifications) (24). A third study by 
Jaffe et.al. has similarly found difficulty in predicting immunologic phenotype 
by morphologic criteria alone (44). These authors were only able to correctly 
predict immunologic phenotype in 61% of 29 cases of diffuse aggressive 
Non-Hodgkin's lymphomas. 
The second criticism stated in this paper concerns the "U-cell" class 




to comprehend or elucidate. If the U-cell is defined by lack of surface marker 
then it becomes a heterogeneous group that can have little predictive value, 
and thus Lukes and Collins have introduced a term which is at best, ambiguous. 
They claim that more than thirty percent of histiocytic lymphomas do not have 
cell markers and would thus be classified as U-cell. In addition, they claim 
that, since in rare cases any morphologic type of NHL may lack surface markers, 
there is no consistent correlation between morphology and immunology in the 
U-cell category (28). 
Another major criticism that has been cited against the Lukes-Collins 
classification is the lack of emphasis placed upon the architectural pattern of 
the lymphomas. Nathwani et al separated their cases by both Lukes-Collins 
classification as well as by architecture and compared survival times. What 
they found was that within each Lukes-Collins class, nodular architecture 
conferred a better prognosis. Thus, they claim that even if nodularity has no 
conceptual relevance it does provide prognostic information and should be 
included in any classification scheme (28). This conclusion is supported more 
recently in the National Cancer Institute study of the classifications of the 
NHL which will be discussed later. This study too showed an association 
between nodularity and survival independent of cell type (24). 
Nathwani has also criticized the Lukes-Collins classification by stating 
that they found no apparent significance in dividing the histiocytic lymphomas 
of Rappaport into five categories. They did find that the large cleaved FCC 
lymphomas did better, but found no difference among the rest. In addition, 
they claimed that it was difficult to separate this group by morphology alone 
and thus question its ultimate usefulness. Recently however, a study by 

25 
Van der Valk et. al. (39) investigated this problem and concluded that by using 
morphometric cell parameters alone, including nuclear size and shape, cytoplasm 
t 
area, and cytoplasm to nucleus ratio, it was possible to separate the large 
non-cleaved FCC lymphomas from the immunoblastic sarcomas and from "true" 
histiocytic lymphomas. 
In the most recent paper by Nathwani et. al. (64) the authors did not 
specifically comment on the difficulty they encountered subdividing the DHL by 
the Lukes-Collins classification. However, 59 out of 279 (21%) cases were 
found to be of suboptimal technical quality for precise subcalssifications. Of 
the cases used in the study a consensus was reached regarding subclassification 
in 129 of 162 (80%). This corresponds with other studies (23,37) which 
reported on the reproducibility of the Lukes-Collins classification. No 
significant difference in survival was found, using these 162 cases, between 




Dorfman Classification: Proposed first in 1974, the Dorfman classification 
is a compromise between the Rappaport, Lukes-Collins, and the BNLI 
classifications and represents an attempt to eliminate controversial 
terminology, such as "histiocyte". Like that of Rappaport, the Dorfman 
classification makes a distinction on the basis of architecture and does not 
use B and T cell terminology (40). 
BNLI Classification: Proposed in 1973, the BNLI classification is 
essentially a modification of the Rappaport system that recognized the 
follicular center origin of nodular lymphomas. It separates the NHL also into 
two grades: Grade I, with a better prognosis, comprised of the nodular 
lymphomas and the more well-differentiated ones, and Grade II, comprised of the 
histiocytic lymphomas and those that are poorly differentiated (41). 
WHO Classification: The classificaton of the World Health Organization is 
acknowledged as a compromise based on our current limited understanding of the 
lymphomas. It is "...subject to further modification as new knowledge 
accumulates on the precise origin of the tumor cells" (42). This 
classification groups the NHL by architecture. 
Kiel Classification: Proposed by Lennert and his collaborators, the Kiel 
classification is widely used in Europe. This system does not separate by B or 
T cell origin, but uses the words "centrocyte" and "centroblast" to refer to 
what Lukes and Collins call "cleaved" and "non-cleaved" cells respectively. 




The NCI Sponsored Study of the Classifications of the Non-Hodgkin's Lymphomas 
It should now be apparent how this explosion of "definitive” 
classifications, while indeed providing useful information and fuel for debate, 
was able to confuse even the most dedicated physician. With at least six major 
classificatons (and just as many minor ones) it became difficult for the 
average physician to interpret the literature on the NHL and compare studies 
done at different centers using different classification. 
In 1981 the NCI sponsored a study in an attempt to eliminate some of this 
confusion. Taking pathologic material from 1175 cases of NHL, slides were 
presented to each of six "experts" who were proponents of one of the major 
classifications. The slides were also presented to six "experienced" 
pathologists not connected to a particular classification. Each pathologist 
reviewed each slide using ordinary H & E stains and gave his or her diagnosis. 
The "experts" used the classification scheme they were the proponent of, while 
the "experienced” pathologists classified each slide by each of the 
classifications. Slides were also resubmitted to each pathologist to test 
reliability. The diagnoses were then correlated with clinical information from 
each case. 
The major conclusion of the study (much to the relief of the "experts") was 
that "...all six classifications were valuable and comparable in 
reproducibility and clinical correlations." In addition, it was concluded that 
each system separated the patients into subgroups with varying prognoses, from 
good to poor, and no system was superior to any other in this regard. This 
study also confirmed previous observations that those lymphomas which display a 
nodular (follicular) architecture have a better prognosis than those with a 
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diffuse architecture. Finally, from the work done in this study, a "working 
formulation" for the classification of the NHL was proposed which, using 
morphologic criteria alone, subdivides the NHL into ten groups. Sub-* 
classifications are provided as a means by which translation can be made 
between each of the six major systems to facilitate comparison of clinical 
reports and therapeutic trials. This working formulation is presented in Table 
6. This formulation makes no provision for B or T cell categories. 
Summary of Classification Systems 
It should be clear by now that the search for an easy, reproducible, 
scientifically accurate, and prognostically relevant classification scheme for 
the NHL is far from over. The Rappaport system has been proven to be 
prognostically significant but appears scientifically out-moded. The Lukes- 
Collins classificaton, while including the latest in immunologic research, 
appears difficult to use at the present time. The "working formulation” 
developed by the NCI is a worthwhile attempt to provide a "universal 
translator" but since it does not include T or B cell terminology it appears 
already "old fashioned". 
The search for the "definitive" classification scheme will progress while 
our knowledge of immunology moves forward. Ultimately a more ideal 
understanding of normal lymphocytes and lymphomatous cells will allow us to 




Table 6. WORKING FORMULATION OF NCI STUDY OF NHL CLASSIFICATION 
LOW GRADE 
A. Small Lymphocytic 
- consistent with CLL 
- plasmacytoid 
B. Follicular, small cleaved cells 
- diffuse areas 
- sclerosis 
C. Follicular, mixed small and large cell 
- diffuse areas 
- sclerosis 
INTERMEDIATE GRADE 
D. Follicular, large cell 
- diffuse areas 
- sclerosis 
E. Diffuse, small cleaved cells 
- sclerosis 
F. Diffuse, mixed small and large cell 
- sclerosis 
- epithelioid cell component 
G. Diffuse, large cell 
- cleaved cell 
- non-cleaved cell 
- sclerosis 
HIGH GRADE 
H. Large Cell, immunoblastic 
- plasmacytoid 
- clear cell 
- polymorphous 




J. Small Non-cleaved Cell 
- Burkitt’s 







(Adapted from NCI study of classifications of NHL (24)) 
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DIFFUSE HISTIOCYTIC LYMPHOMA 
Diffuse Histiocytic Lymphoma (DHL) is one of the most common subtypes of 
the Rappaport classification of the NHL, comprising about one third of all 
non-Hodgkin's lymphomas. Since it was originally described by Rappaport, DHL 
gained the reputation as being a highly aggressive neoplasm that was refractory 
to treatment (46). However, over the last fifteen years great advances have 
been made in its treatment, especially in the area of combination chemotherapy, 
so that it is now considered a "potentially curable" neoplasm (47). It has 
been demonstrated that in actuality DHL is comprised of a group of neoplasms 
with widely divergent histology, natural history, and response to treatment. 
Complete response rates up to 69% have been achieved (48) but there remains a 
large group that has proven to be unresponsive to treatment. Many attempts 
have been made to identify this sub-group in advance of treatment and 
investigation continues to develop aggressive treatment for it. The study 
j 
which follows is one such attempt. Before the study is presented prognostic 
factors in DHL will be discussed followed by a review of current treatments for 
the disease. 
Prognostic Factors in DHL 
Site of Involvement: Numerous studies have discussed site of primary 
involvement as a prognostic factor in DHL. However no consistent conclusion 
can be drawn from these studies. A retrospective review by Fisher et. al. (49) 
identified gastrointestinal involvement and hepatic involvement as predictors 
. 
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of a poor prognosis for patients with diffuse histiocytic, mixed, or 
undifferentiated lymphomas. Other studies however have discounted GI or liver 
involvement (50,51) as a poor prognostic factor. Presence of a "huge"*GI tumor 
( 10 cm), and involvement of the CNS have similarly been correlated with poor 
prognosis but there appears to be no consensus on this issue (36, 49-53). A 
study by Strauchen (36) indicated a high correlation between iramunoblastic 
sarcomas and CNS and GI involvement which might account for the occasional 
finding of poor survival among patients with involvement at these sites. 
Invasion of the bone marrow seems to be correlated with poor prognosis and this 
Is supported by a number of studies (49-53). 
Laboratory studies: There is some indication that serum LDH y 250 u/liter 
is a predictor of poor survival (49) although some authors have suggested that 
levels above 500 U/liter are more significant (50). A hemoglobin level of less 
that 12 mg/ml was identified as a predictor of poor prognosis in one recent 
study (51). This study also found no correlation between Erythrocyte 
Sedimentation Rate and prognosis. 
Age/Sex: Again the literature presents a mixed picture but age and sex do 
not seem to be correlated with survival. However one study found that male sex 
was a poor prognostic factor (49) while another found that age greater than 60 
years was correlated with poor survival (51). 
Stage: Staging of the NHL in general, and DHL in particular, has not 
proven to be as clinically useful as it has in Hodgkin's disease. 
Theoretically, Rosenberg (54) has suggested, a staging system should 1) provide 
prognostic information, 2) assist the physician in selecting therapy, 3) 




the extent of the disease. The Ann Arbor scheme for the staging of Hodgkin's 
disease (see Table 7) has been applied to the NHL and has fulfilled the last 
three of these goals. It has not however, supplied much in the way of 
prognostic information. For example a patient with nodular poorly- 
differentiated lymphocytic lymphoma may present with stage IV disease but may 
run an indolent course, while a patient with DHL may have a much poorer 
prognosis even though he/she may present with stage II disease. It has been 
suggested that clinicians use a sequential staging scheme based on the Ann 
Arbor staging system while being aware that other factors weigh more heavily in 
the determination of prognosis (55). (See Table 8). 
Pathology: Most studies have indicated that the single most important 
factor in determining prognosis is pathological classification. As it has 
already been discussed, in the Rappaport classification, a good prognosis is 
indicated by a nodular lymphoma or one composed of lymphocytes. However the 
Rappaport classification make no attempt to separate lymphomas of the diffuse 
histiocytic type into different groups. The Lukes-Collins classification 
divides the DHL into five categories which have been discussed. There appears 
to be some difference among these five groups in terms of prognosis but this is 
still a controversial point. 
, 
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Table 7. ANN ARBOR STAGING CLASSIFICATION 
Stage I 
Involvement of a single lymph node region (I) or localized 
involvement of a single extranodal organ/site (Ie). 
Stage II 
Involvement of more than one lymph node region on the same 
side of the diaphragm (II) or of one or more lymph node regions 
and localized involvement of an extralymphatic organ/site (lie) 
on the same side of the diaphragm. 
Stage III 
Involvement of lymph node regions on both sides of the 
diaphragm (III) which may be accompanied by involvement of 
the spleen (Ills) or by localized involvement of an 
extralymphatic organ/site (Ille) or both (Illse). 
Stage IV 
Diffuse or disseminated involvement of one or more extra¬ 
lymphatic organ/site with or without lymph node involvement. 
Table 8. SEQUENTIAL STAGING OF NHL 
Complete history and physical examination 
Routine hematology and chemistries 
Standard chest radiography 
Metastatic skeletal survey 
Isotopic bone/liver-spleen scanning 
Bipedal lymphangiography 
Bone marrow biopsy 
Percutaneous liver biopsy 
Liver biopsies via peritoneoscopy 
Staging laparotomy 
(From Chabner et. al. (55)) 
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Treatment of Diffuse Histiocytic Lymphoma 
Treatment of localized DHL 
Approximately 20-30% of patients with DHL present with localized (Stage I 
or II) disease. Sweet and Golumb have recently reviewed their experience with 
radiation therapy in localized DHL. Treating 28 patients with stage I or II 
disease they found that patients with stage I disease achieved a median 
survival of 72.5 months and a 93% 11 yr. actuarial disease free survival. 
Patients with stage II disease fared much worse with a median survival of 33 
months and an 11 yr. actuarial survival of 33%. Many centers now treat stage I 
disease with radiation therapy alone and treat stage II with adjuvant 
chemotherapy or chemotherapy alone (56). 
Treatment of advanced DHL 
The treatment of advanced DHL (stages II-IV) has changed considerably in 
the last decade. Far from the aggressive neoplasm which carried a uniformly 
poor prognosis, DHL is now considered a "potentially curable" neoplasm. Single 
agent chemotherapy in the sixties was disappointing, producing few complete 
remissions, with 5-10% of patients achieving a complete remission and median 
survival averaging less than one year. Treatment with CVP (cyclophosphamide, 
vincristine, and prednisone) increased the complete remission rate but did not 
affect survival (48). In the early seventies aggressive combination 
chemotherapy was found to be successful in patients with Hodgkin's disease 
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(nitrogen mustard, vincristine, procarbazine, and prednisone) and using 
cyclophosphamide in place of nitrogen mustard DeVita achieved a complete 
♦ 
remission rate, for patients with DHL, of a rather low 50% but found that this 
remission was very durable, 91% of the complete responders remaining disease 
free for 26-105 months (47). In 1972 and 1975, researchers at Yale, using a 
regimen called COMA (cyclophosphamide, vincristine, methotrexate with 
leucovorin, and cytosine arabinoside) reported similar durable remissions in 
6/8 patients (57). 
Since the advent of the newer antitumor antibiotics, adriamycin and 
bleomycin, numerous regimens testing the efficacy of these drugs have been 
devised. The trials of these newer combinations have been numerous and the 
details of each are beyond the scope of this paper. Sweet and Golomb have 
reviewed the current status of the combination chemotherapy of DHL (48). A 
table giving the results of some of these studies can be seen in Table 9. It 
has proven difficult to compare the results of these studies for a number of 
reasons. First of all, even though the acronyms used in different studies may 
be the same, the dosage and administration schedules are often different. 
Second, there are often differences in restaging techniques done after 
achievement of a complete remission so that the meaning of remission may vary 
from one study to another. In addition, some studies use maintenance 
chemotherapy in addition to the initial therapy while others do not. Finally 
the number of patients in each study is often small making statistical 
significance difficult to achieve. 
Since the review by Sweet and Golumb, two new combinations of standard 
chemotherapeutic agents have been published. Laurence et. al. (58) have 
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reported the results of a study of a six-drug chemotherapy regimen called 
COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and 
f 
procarbazine) administered to patients with stage III and IV DHL. They 
achieved a complete remission rate of 73% and partial response rate of 24%. 
Median survival has not yet been reached. Ginsberg et. al. (59) recently 
reported a trial of cyclophosphamide, doxorubicin, vincristine combined with 
continuous infusion of low-dose bleomycin. The rationale for the continuous 
infusion of bleomycin, rather than the bolus administration found in other 
regimens, was an attempt to reduce pulmonary toxicity while keeping a steady 
state therapeutic level of bleomycin. Complete remission rate from this study 
was 77% for DHL patients who had had no prior chemotherapy while no patient in 
the study developed pulmonary toxicity (n=37). 
A few conclusions are possible from the data generated at the various 
centers; 1) There are numerous chemotherapeutic regimens that are successful in 
achieving complete remission in DHL, 2) remission rates vary between 41-69%, 
3) regimens using maintenance therapy have not produced more durable remissions 
than those without maintenance therapy, 4) cures appear to be possible only 
after the achievement of a complete remission and patients remaining in 
remission for two years appear to be cured of their disease (48). 
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Table 9. A COMPARISON OF CHEMOTHERAPEUTIC TREATMENT OF ADVANCED DHL 
Regimen 
Complete 
response rate % 50% survival Comments 
COMA 75% — 
f 
selected series 
C-MOPP 41% 9 restaged; few relapses 
after 2 yrs if CR 
BACOP(NCI) 48% 14 selected series 
CHOP/HOP 68%/66% 23 +maintenance 
BACOP(Farber) 56% 9 +maintenance 
COMA 40% 9 selected series 
CHOP + Bleo 61% 25(approx) some with BCG 
COMLA 55% +25 unselected 
COP-BLAM 73% +26 50% survival not 
reached yet 
C = Cyclophosphamide 
0 = Vincristine 
M = Methotrexate (ex C-MOPP where M=Nitrogen mustard) 
A = Cytosine arabinoside (ex COP-BLAM where A=Adriamycin) 
P = Prednisone 
PP = Prednisone + Procarbazine 
B = Bleomycin (also BL) 
H = Adriamycin 
L = Leucovorin rescue 
(adapted from Sweet and Golomb (48)) 
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A RANDOMIZED TRIAL OF ACOMLA AND CHOP-BLEO IN ADVANCED DHL 
t 
Introduction to Study 
A randomized trial of two chemotherapy treatments was initiated in 1975 
with two main goals. The first was to compare the efficacy of a new regimen 
ACOMLA to that of a commonly used drug combination CHOP-Bleo (descriptions 
below) for the treatment of advanced DHL. The second goal was to see if the 
Lukes-Collins classification was able to identify subsets of DHL that were 
unresponsive to treatment so that these subsets could be identified 
prospectively and more aggressive treatments designed for them. 
Individual Chemotherapeutic Agents 
Cyclophosphamide (Cytoxan) is an alkylating agent that acts by inactivating 
DNA, which may be administered both intravenously or orally. It is not cell 
cycle specific and causes most of its toxicity during the S-phase. Bone marrow 
suppression is common and is the limiting toxicity. Nausea, vomiting and 
alopecia are common (60). 
Doxorubicin (Adriamycin) is an anthracycline antibiotic which binds DNA 
permitting intercalation thus impairing the template activity of the DNA. The 
drug may only be given intravenously. Myelotoxicity is the major complication 
and nausea, vomiting and alopecia are common. Tissue necrosis can occur if the 
drug extravasates during administration. This drug causes an unusual form of 
cardiomyopathy which may be fatal, although death is rare with total dosage of 
less than 500 mg/m2 (60). 
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Vincristine (Oncovin) is a derivative of an alkaloid found in the 
periwinkle Vinca rosea. Its mechanism of action is not clearly defined but it 
is thought to inhibit the cell cycle at metaphase by damaging spindle ’protein. 
It is only administered intravenously and does not cause myelosuppression. 
Neurotoxicity is common and reversible paresthesias may occur (60). 
Methotrexate is a folate antagonist that acts by inhibiting the enzyme that 
catalyzes the reduction of dihydrofolate to tetrahydrofolate. The result of 
this is inhibition of DNA synthesis. It is cell cycle specific and causes cell 
death during the S-phase. Leucovorin (folinic acid) is administered after high 
or intermediate dose methotrexate to decrease toxicity. Toxicity includes 
renal crystal formation, myleosuppression, nausea, vomiting and vasculitis 
(60). 
Cytosine Arabinoside (Cytarabine, Ara-C) is an analogue of deoxycytidine 
that has a structural alteration in the sugar moiety and acts by inhibiting DNA 
polymerase. It is cell cycle specific acting during the S-phase. Its major 
toxicity is myelosuppression (60). 
Bleomycin is an agent isloated from Streptomyces verticillus which kills 
dividing cells by causing chain fragmentation of DNA. It is administered 
intravenously. Its most common toxicity is pulmonary fibrosis which generally 
occurs at doses over 400 units. The development of diffuse interstitial 
fibrosis can be anticipated by a decrease in diffusing capacity (60). 
Prednisone is a corticosteroid which acts on neoplastic cells by an unknown 
mechanism. Side effects include GI bleeding, electrolyte imbalances, and 
alterations in the psyche (60). 
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The Therapeutic Regimens 
The two chemotherapeutic regimens used in this study are called CfrOP-Bleo 
and ACOMLA. CHOP-Bleo has been used since 1972 and has been reported to result 
in a complete remission rate of 65% (61). It utilizes cyclophosphamide, 
hydroxydaunorubicin, vincristine, prednisone and bleomycin. The ACOMLA regimen 
evolved from COMLA with the addition of hydroxydaunorubicin. COMLA was used by 
Sweet et. al. and is reported to yield a complete remission rate of 55% (52). 
COMLA was developed to utilize the established agents cyclophosphamide and 
vincristine for tumor lysis which was then followed by methotrexate and 
cytosine arabinoside, which kills cells that are synthesizing DNA, for maximum 
cell kill during the period of rapid growth. In addition, methotrexate and 
cytosine arabinoside have been shown to act synergistically by enhancing 
intracellular accumulation of the latter (62). The latter two agents also 
cross the blood-brain barrier which might help prevent CNS relapses (63). 
Materials and Methods 
Between May 1976 and April 1982 patients were entered into Yale Human 
Investigations Committee protocol #1257 (approved May 26, 1976). Conditions 
required for entry were: 
1) A diagnosis of diffuse histiocytic lymphoma (Rappaport) 
2) Slides of original biopsy material available for review at Yale 
3) Stage III or IV disease (Ann Arbor classification) 
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4) No previous chemotherapy 
5) Measurable disease (by physical exam or otherwise) 
6) Granulocyte count greater than 500 cells/mm3 
7) Platelet count greater than 50,000/mm3 
8) Age greater than 16 years (no upper limit) 
9) Ability to give informed consent 
Patients were not excluded with prior radiotherapy (unless this included 
all sites known to have disease), poor Karnovsky status, or concurrent medical 
illnesses. 
All patients received the following evaluation: 
1) Complete history and physical examination 
2) Complete blood count, liver and renal function tests 
3) Chest X-ray 
4) Bilateral (iliac crest) bone marrow biopsy (with aspiration if 
possible) 
5) Lymphangiography with intravenous pyelogram 
6) Gallium scan 
7) Liver-spleen scan 
8) Abdominal ultrasound, CT scan, GI series (if GI involvement or GI 
symptoms) 
9) Lumbar puncture for cytology (if bone marrow involved) 
10) MUGA scan (if at risk for adriamycin cardiotoxicity) 
11) Pulmonary function tests (if at risk for pulmonary toxicity) 

42 
In addition, original slides of biopsy material were reviewed blindly and 
classified according to the Lukes-Collins classification. 
Each patient was randomly (by coin-toss) assigned to either the CtfbP-B or 
ACOMLA treatment arms. These treatments consisted of: 
2 
ACOMLA: Adriamycin 40 mg/m 
9 
IV Day 1 
Cyclophosphamide 1 g/m IV Day 1 
3 CYCLES Vincristine 2 mg IV Days 1,8,15 
Methotrexate 
Z 
120 mg/m IV 
Leucovorin 25 mg q6hx6 P0 Days 22,29, 
2 50,57,71 





IV Day 1 
Cyclophosphamide 1 mg/m IV Day 1 
9 CYCLES Vincristine 2 mg IV Days 1,5 
Bleomycin 15 Units 
9 
IV Days 1,5 
Prednisone 100 mg/m PO Days 1,5 
Each treatment lasted nine months (3 cycles of ACOMLA or 9 cycles of 
CHOP-B). Additional cycles were used when there was a question of persistent 
disease. Patients at risk for the toxic effects of chemotherapy were 
identified and treatment was reduced. These patients were identified by 1) 
increased age, 2) extensive radiotherapy or bone-marrow involvement, 3) 
elevated bilirubin, 4) history of heart failure or arrythraias, 5) poor 
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pulmonary function. Dosages were modified according to Table 10, for decreased 
granulocyte count, nausea and vomiting, pulmonary fibrosis, diabetes mellitus, 
history of psychosis, paresthesias, and muscle weakness. 
One month after completion of therapy all patients were restaged using the 
same procedures described in the initial evaluation. If previous sites of 
disease had clinical evidence of continued disease these sites were 
re-biopsied. Patients were then followed at two month intervals for two years 
then followed at six month intervals. A complete response (CR) was defined as 
total disappearance of disease for one month after chemotherapy. A partial 
response (PR) was defined as a reduction in tumor size of at least 50% for at 
least one month. Any response less than this was considered a non-response 
(NR). Patients who failed to respond at all to chemotherapy were considered 
indiction failures. These were included in statistical analysis as 
non-responders. 
Survival was calculated from the date of protocol entry. Freedom from 
relapse was calculated from the date of objective CR to date of documented 
relapse or date patient was last seen and known to have continued in CR after 
reevaluation. Most patients obtaining CR did so within two months of 
initiation of therapy. To eliminate observer subjectivity, freedom from 
relapse was also calculated for those acieving CR from the date therapy ended 
to the same end point as previously mentioned. This calculation was used 
unless otherwise stated. Survival was correlated with certain factors that 
have been associated with prognosis. These were: age, sex, size of mass, 
presence of bone marrow involvement, CNS involvement, GI involvement, and 
Lukes-Collins pathology. Survival curves were calculated and compared using 
the Wilcoxon test. 
1 
Table 10. DOSE MODIFICATIONS 
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1. Hematologic 
a. Regimen A 
f 
i. Decrease adriamycin and cyclophosphamide by 1/3 if the nadir 
granulocyte count achieved is less than 300/mm3 
ii. Decrease MTX and cytosine arabinoside by 1/3 if WBC, at time 
of treatment, is 2,500 to 3,500/mm3. Omit dose if WBC is 
less than 2,500/mm3 
iii. Decrease MTX by 40mg/m2 increments if WBC^L4,000/mm3 
prior to dose. 
b. Regimen B 
i. Decrease adriamycin and cyclophosphamide dose by 1/3 if 
nadir granulocyte count after previous dose is less than 
300/mm3. 
ii. Wait 1 week if WBC <,3,000/mm3 at 3 weeks. 
2. Other 
a. Cytosine Arabinoside - decrease to 100mg/ra2 for protracted 
unmanageable nausea and vomiting. 
b. Adramycin - limit total accumulative dose to 450mg/m2 
(adriamycin + cyclophosphamide increases cardiotoxicity) Omit 
if bilirubin>3mg%. 
c. Bleomycin - limit total accumulative dose to 300mg total 
(Pulmonary fibrosis occurs occasionally after this dose) 
d. Prednisone - omit if ulcer history or symptoms. Omit if 
diabetes mellitus or history of psychosis. 
e. Vincristine - reduce 50% for severe paresthesias or unmanageable 
constipation. Omit for profound muscle weakness, foot drop or 
ileus. Give only 1 mg total dose for age65 yrs. 
f. Methotrexate - do not escalate as outlined above if WBC not 




During the study period, between Kay, 1976 and April, 1982, a total of 54 
patients were entered into the protocol. Of these, 4 were omitted from 
analysis on pathology review, having lymphomas other than the diffuse 
histiocytic type. Another two were omitted because on review they were found 
to have only stage I or II disease. Of the remaining 48, two did not have a 
Lukes-Collins classification specified at the time of review so they were 
omitted from this part of the analysis. Tables 11 and 12 show the general 
characteristics of the patient population. The median age for all patients was 
58.4 and the sex ratio was 28:20, with females predominating. 
Table 11. CLINICAL CHARACTERISTICS BY LUKES-COLLINS PATHOLOGY 
STAGE SITES MASS REMISSIONS Rx 
// III IV Sx BM GI 
Lukes-Collins 
lclFCC 13 4 9 4 4 1 
IncFCC 7 2 5 2 0 2 
B-IBS 14 5 8 4 3 5 
T-IBS 8 4 4 4 2 1 
LCU 4 1 3 0 0 0 
lclFCC = large cleaved FCC 
IncFCC = large non-cleaved FCC 
B-IBS = B Cell immunoblastic sarcoma 
T-IBS = T Cell immunoblastic sarcoma 
LCU = large cell unclassified 
CNS >10cm CR PR NR A C 
0 1 8 4 0 6 7 
0 3 6 0 1 0 7 
0 4 8 3 3 6 8 
0 1 5 2 1 5 3 
0 1 4 0 0 3 1 
Rx A = ACOMLA 
Rx C = CHOP -B 
Sx = "B" symptoms 
Table 12. CLINICAL CHARACTERISTICS BY TREATMENT 
Rx AGE SEX STAGE SITES MASS 
(mean) M F III IV BM GI CNS > 10cm 
ACOMLA 59.1 12 8 4 16 6 3 0 3 
CHOP-B 57.8 8 20 13 15 3 7 0 7 
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ACOMLA vs. CHOP-B 
Of the 48 patients, 20 were treated with ACOMLA and 28 were treate'd with 
CHOP-B. Of the ACOMLA patients one had not yet been restaged at the time of 
analysis and, although he was described as being in clinical remission, he was 
not included in the analysis. Most patients who achieved a complete remission 
did so during the first two months of therapy. The response rates are listed 
in Table 13. There was no significant difference in response rates between the 
two treatments. 
Table 13. RESPONSE RATES 
Rx CR PR NR 
ACOMLA 13/19 (68%) 4/19 (21%) 2/19 (11%) 
CHOP-B 20/28 (71%) 5/28 (18%) 3/28 (11%) 
TOTAL 33/47 (70%) 9/47 (19%) 5/47 (11%) 
Of those patients achieving a complete response there were 7 patients who 
had a relapse. 4 of these had bee treated with ACOMLA and 3 with CHOP-B. The 
time to relapse ranged from 2 months to 32 months (mean 10 months) with no 
significant difference between the two treatment arms. Of those patients with 
a CR, 6 have died. Four of these died after a relapse with progression of 
their disease (2 ACOMLA, 2 CHOP-B). The other two deaths were apparently 
■ 
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unrelated to their lymphoma. One died a sudden death 8 months after therapy 
while the other died with a pneumonia 14 months after therapy. 
The median survival for all patients has not yet been reached. The* median 
follow-up time is 32 months (37 for ACOMLA patients, 29 for CHOP-B patients). 
Of those patients who did not respond to therapy the median survival time was 
less than 6 months. Of those patients who obtained only a partial response, 5 
are alive on various chemotherapeutic agents while the median survival of the 
other 4 was 12 months. 
Drug toxicity was substantial. There were three drug-related deaths (2 
ACOMLA, 1 CHOP-B). Two patients developed bleomycin toxicity demonstrated by a 
decrease in pulmonary function tests. Three patients developed adriamycin 
cardiotoxicity (1 ACOMLA, 2 CHOP-B). Six patients developed neurotoxicity from 
the vincristine (1 ACOMLA, 5 CHOP-B). There was a small difference in sepsis 
between the two treatment arms with 37% of ACOMLA patients and 18% of CHOP-B 
patients having treatment-related sepsis. This difference was not significant 
(p=0.17). 
Prognostic factors 
There was no correlation between the patients age, stage, symptoms, sex, GI 
tract involvement, or tumor size, and survival that proved to be statistically 
significant. There was, however, a trend for older patients to do poorly, but 
again, not in a statistically significant manner. For reasons that are not 
clear there were more females "randomized" to the CHOP-B treatment arm and more 
stage IV patients to the ACOMLA treatment arm. These differences were 
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significant. However, since neither age nor stage were correlated with 
survival, this had no effect on the study. No patients in the study had 
t 
involvement of the CNS so this could not be analyzed as a prognostic factor. 
Nine patients (19%) presented with bone marrow involvement. While this 
does not adversely affect survival in a statistically significant manner, it 
should be noted that only one of these patients has achieved a documented 
complete remission and this patient had a relapse two months after completion 
of therapy. Another is in clinical remission but has not been restaged. The 
others achieved a partial remission. It is interesting to note that the two 
patients with bone marrow involvement who attained a CR had been treated with 
ACOMLA. In view of the small numbers involved it would be unwarranted to draw 
any conclusions from this. 
Table 10 shows the distribution of patients by Lukes-Collins pathology. 
For analysis, patients were grouped into immunoblastic sarcomas (T and B cell 
types) and "others" (lclFCC, IncFCC, and large cell unclassified). There was a 
decrease in survival for patients with immunoblastic sarcomas (p=0.01) but 
there was no difference in relapse free survival. There was no difference 
between the FCC cleaved and non-cleaved types with regards to survival. 
There were four cases of patients with second malignancies: squamous cell 
carcinoma of the lung, carcinoma of the prostate, acute myelogenous leukemia, 
and grade I transitional cell cancer of the bladder. The first two were found 
in patients treated with CHOP-B within one year of attaining CR. The patient 
with AML was diagnosed one month after completion of ACOMLA. The case of 






This study was originally designed for two reasons. The first was to 
compare the new regimen ACOMLA with CHOP-B in the treatment of advanced diffuse 
histiocytic lymphoma. The second was to identify factors (eg. Lukes-Collins 
classification) that would be useful in defining that subset of DHL with a poor 
prognosis and refractory to treatment. 
As was mentioned in the section on "treatment” the ACOMLA regimen evolved 
for several theoretical reasons. The anti-metabolites methotrexate and 
cytosine arabinoside are given after tumor lysis to insure maximum cell kill 
during the period of rebound growth. Administration of cytosine arabinoside 
after methotrexate has been shown to increase its intracellular concentration. 
In addition, these two drugs have been shown to cross the blood-brain barrier 
and thus, it is supposed, might help to prevent CNS relapses which have proven 
to be problematic in other studies (65). 
The results of this study indicate that there is no difference in outcome 
between either treatment, measured by response rates and survival. There is a 
trend (not significant) toward greater toxicity with ACOMLA. The question of 
whether or not ACOMLA was useful in preventing CNS relapses was not answered by 
this study. There were only 9 patients who were at risk for a CNS relapse 
(with bone marrow involvement) and only one of these attained a documented 
complete remission. It is interesting to note that in patients who had bone 
marrow involvement and thus were at risk for CNS relapse, the dosage of cyclo¬ 
phosphamide and adriamycin was reduced by 33% (by protocol) to avoid dangerous 
bone marrow suppression. It may be that with these patients the risk of bone 
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marrow toxicity may have to be balanced against the desire to attain a complete 
remission and the dosage should not be reduced. 
There appears, then, at this time, no reason to recommend ACOMLA over 
CHOP-B. CHOP-B is cheaper ($2700 for CHOP-B, $3700 for ACOMLA), easier to 
give, and has a slightly lower rate of toxicity, but ACOMLA may prove to be 
more effective for patients with marrow involvement and uses a lower total 
dosage of adriamycin. 
The results of this study indicate that GI involvement, tumor size, age, 
sex, stage, or presence of symptoms, were not useful in identifying that subset 
of patients with a poor prognosis. This is in agreement with data from some 
centers but is in disagreement with others. There is no apparent explanation 
for this difference. Hematocrit and serum LDH levels were correlated with 
prognosis in one study but were not included in the present one. There was a 
trend for patients with bone marrow involvement to have difficulty in attaining 
a complete remission and the one patient with a documented CR had a relapse two 
months later. The number of patients with bone marrow involvement were small, 
however, and this was not a statistically significant finding. 
The ability of the Lukes-Collins classification to identify subsets of DHL 
with varying prognoses is currently a controversial subject. As was discussed 
above, some studies find that the large-cell FCC lymphomas have a better 
prognosis than the immunoblastic sarcomas, while others dispute this finding. 
Some studies have shown the large cleaved FCC lymphoma to have a better 
prognosis than the large non-cleaved variety, while one study reports the 
opposite. Still other studies have indicated no significant differences in 
survival between any of the large cell lymphomas. 
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It is difficult to explain why this controversy exists in the literature. 
There have been few studies that are prospective randomized trials with the 
f 
patients given uniform treatment. Sample sizes are small which makes it 
difficult to compare results from different centers. In addition, there is the 
apparent difficulty in using the Lukes-Collins classification which may result 
in slight variances in interpretation of the histologic subclassifications, 
there does seem, however, to be a distinct trend for the FCC lymphomas to have 
a better prognosis than the iramunoblastic sarcomas. The results of this 
current series supports this conclusion. There was no difference found between 
the cleaved and non-cleaved FCC lymphomas. It is important to note that the 
relapse-free survival for the FCC and immunoblastic lymphomas was the same. 
What this indicates is that once a patient achieves a complete remission 
his/her survival is independent of histology. Thus it is apparent that the 
Lukes-Collins classification does indeed identify a subset of DHL that carries 
a poor prognosis and is refractory to current treatment. It can be inferred 
from this that a more efficacious treatment should be designed for these 
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